Get the Stockscreener App
3.18
0.63%
-0.02
Pre-market:
3.18
Ventyx Biosciences Inc stock is traded at $3.18, with a volume of 469.83K.
It is down -0.63% in the last 24 hours and up +32.50% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$3.20
Open:
$3.17
24h Volume:
469.83K
Relative Volume:
0.30
Market Cap:
$226.29M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-0.9636
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+0.47%
1M Performance:
+32.50%
6M Performance:
+41.33%
1Y Performance:
+9.66%
1-Day Range:
$3.13
$3.21
1-Week Range:
$2.881
$3.2999
52-Week Range:
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
3.18 | 227.72M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Ventyx Biosciences Inc. stock chart pattern explained High Confidence Strategy with Trend Alignment - Newser
Is it time to cut losses on Ventyx Biosciences Inc. Momentum Screener with Buy and Sell Areas - Newser
Will Ventyx Biosciences Inc. rebound enough to break even Weekly Price Target Forecast and Alerts - Newser
Should I hold or sell Ventyx Biosciences Inc. stock in 2025Exceptional profit velocity - jammulinksnews.com
What are the latest earnings results for Ventyx Biosciences Inc.High-impact investment strategies - jammulinksnews.com
Ventyx Biosciences Inc. Stock Support and Resistance Levels You Should KnowSolid Return Trade Selections - beatles.ru
How volatile is Ventyx Biosciences Inc. stock compared to the marketCapitalize on fast-growing investment opportunities - jammulinksnews.com
How Resilient Is Ventyx Biosciences Inc. Stock During Economic DownturnsHigh Win Rate Stock Ideas - Newser
What is the risk reward ratio of investing in Ventyx Biosciences Inc. stockDiscover stock picks with superior returns - jammulinksnews.com
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionGrowth Stock Monitor - Newser
What analysts say about Ventyx Biosciences Inc. stockExceptional profit velocity - PrintWeekIndia
Ventyx Biosciences Inc. Stock Analysis and ForecastRapid market gains - PrintWeekIndia
Is Ventyx Biosciences Inc. a good long term investmentPowerful market insights - PrintWeekIndia
How Ventyx Biosciences Inc. stock performs during market volatilityPredictable Return Stock Picks - Newser
What drives Ventyx Biosciences Inc. stock priceTremendous growth opportunities - jammulinksnews.com
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000 Value Index - MarketScreener
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.97%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):